Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-LNC1011 in PSMA-positive mCRPC
CTR20260485Phase 2Active
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- Mar 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 225Ac-LNC1011 in prostate cancer (PCa), sponsored by Yantai Lannacheng Biotechnology Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
225Ac-LNC1011
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20260485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260485.